Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances

[1]  Yu-Hong Chen,et al.  Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single‐institute analysis , 2013, Chinese medical journal.

[2]  Yu-Hong Chen,et al.  Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia , 2013, Cancer.

[3]  Xiao-jun Huang,et al.  Immune reconstitution to cytomegalovirus following partially matched‐related donor transplantation: impact of in vivo T‐cell depletion and granulocyte colony‐stimulating factor‐primed peripheral blood/bone marrow mixed grafts , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[4]  J. Kanda,et al.  Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction , 2013, Leukemia.

[5]  A. Nagler,et al.  Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. , 2013, Blood.

[6]  K. Alimoghaddam,et al.  Insights and Hopes in Umbilical Cord Blood Stem Cell Transplantations , 2012, Journal of biomedicine & biotechnology.

[7]  Ya-Zhen Qin,et al.  Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia , 2012, Journal of Hematology & Oncology.

[8]  Lanping Xu,et al.  Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation , 2011, Journal of Clinical Immunology.

[9]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[10]  F. Aversa,et al.  Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.

[11]  Ş. Akı,et al.  Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[12]  Yu-Hong Chen,et al.  Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies , 2009, Clinical Cancer Research.

[13]  Yu-Hong Chen,et al.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  S. Feig,et al.  Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. , 2008, Blood.

[15]  R. Handgretinger,et al.  Haploidentical SCT in children: an update and future perspectives , 2008, Bone Marrow Transplantation.

[16]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  Q. Jiang,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  Wei Han,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies , 2006, Bone Marrow Transplantation.

[19]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[20]  S. Chevret,et al.  Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. , 2003, Blood.

[21]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[22]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[23]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[24]  T. Lamparelli,et al.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  J. Stockman.  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia , 2013 .